Alternative pharmacologic targets for the treatment of schizophrenia
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alternative pharmacologic targets for the treatment of schizophrenia
Authors
Keywords
-
Journal
CURRENT OPINION IN PSYCHIATRY
Volume 26, Issue 2, Pages 158-165
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2013-01-03
DOI
10.1097/yco.0b013e32835d8296
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Minocycline
- (2012) Olivia M. Dean et al. CNS DRUGS
- The Endocannabinoid System and Schizophrenia: Integration of Evidence
- (2012) Erica Zamberletti et al. CURRENT PHARMACEUTICAL DESIGN
- Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
- (2012) Imran B Chaudhry et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
- (2012) S Miyamoto et al. MOLECULAR PSYCHIATRY
- Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia
- (2012) David Feifel et al. SCHIZOPHRENIA RESEARCH
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- Effects of Moderate-Dose Treatment With Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder
- (2011) L. Elliot Hong ARCHIVES OF GENERAL PSYCHIATRY
- A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
- (2011) Bruce J. Kinon et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial
- (2011) Joo-Cheol Shim et al. NEUROPSYCHOPHARMACOLOGY
- Drug targets for cognitive enhancement in neuropsychiatric disorders
- (2011) Tanya L. Wallace et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Emotion recognition and oxytocin in patients with schizophrenia
- (2011) B. B. Averbeck et al. PSYCHOLOGICAL MEDICINE
- Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia
- (2011) Cort A. Pedersen et al. SCHIZOPHRENIA RESEARCH
- Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial
- (2011) Douglas L. Boggs et al. SCHIZOPHRENIA RESEARCH
- Therapeutic Potential of 5-HT2CReceptor Ligands
- (2011) Nanna H. Jensen et al. TheScientificWorldJOURNAL
- Prospects for Minocycline Neuroprotection
- (2010) Jennifer M. Plane et al. ARCHIVES OF NEUROLOGY
- Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients
- (2010) David Feifel et al. BIOLOGICAL PSYCHIATRY
- A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
- (2010) Robert W. Buchanan et al. BIOLOGICAL PSYCHIATRY
- An Open-Label Tolerability Study of BL-1020 Antipsychotic
- (2010) Ravi Anand et al. CLINICAL NEUROPHARMACOLOGY
- Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia
- (2010) Deanna L. Kelly et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia
- (2010) T Wüstenberg et al. MOLECULAR PSYCHIATRY
- Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
- (2010) Jaime E. C. Hallak et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- Peripheral oxytocin is associated with reduced symptom severity in schizophrenia
- (2010) Leah H. Rubin et al. SCHIZOPHRENIA RESEARCH
- A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
- (2010) Akihiro Shiina et al. Annals of General Psychiatry
- TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia
- (2009) T.A. Hauser et al. BIOCHEMICAL PHARMACOLOGY
- Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum Disorders
- (2009) Adam J. Guastella et al. BIOLOGICAL PSYCHIATRY
- Antipsychotics in the early stage of development
- (2009) Falko Biedermann et al. CURRENT OPINION IN PSYCHIATRY
- BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans
- (2009) Lieuwe Appel et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- A randomized, double-blind, placebo-controlled comparison study of sarcosine ( N-methylglycine) and d-serine add-on treatment for schizophrenia
- (2009) Hsien-Yuan Lane et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
- (2009) Yechiel Levkovitz et al. JOURNAL OF CLINICAL PSYCHIATRY
- Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism
- (2009) Daniela Cota et al. Obesity
- A Randomized Experimental Investigation of Reasoning Training for People With Delusions
- (2009) K. Ross et al. SCHIZOPHRENIA BULLETIN
- Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder
- (2009) Robert C. Smith et al. SCHIZOPHRENIA RESEARCH
- Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in Schizophrenia
- (2008) David A. Lewis et al. AMERICAN JOURNAL OF PSYCHIATRY
- Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
- (2008) Robert Freedman et al. AMERICAN JOURNAL OF PSYCHIATRY
- Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the α7 nicotinic acetylcholine receptor: In vitro and in vivo activity
- (2008) Brad A. Acker et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia
- (2008) Yona Geffen et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis
- (2008) Donald P Rogers et al. Expert Review of Neurotherapeutics
- Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice
- (2008) H K Caldwell et al. MOLECULAR PSYCHIATRY
- Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system
- (2008) Anna-Leena Sirén et al. Neurotherapeutics
- Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats
- (2008) Amir H. Rezvani et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Sarcosine (N-Methylglycine) Treatment for Acute Schizophrenia: A Randomized, Double-Blind Study
- (2007) Hsien-Yuan Lane et al. BIOLOGICAL PSYCHIATRY
- Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
- (2007) Yuko Fujita et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started